Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

Memorial Sloan-Kettering’s Physician-in-Chief, José Baselga, explains the findings from three studies on new targeted therapies for breast cancer.

At the seventh annual seminar for high school students and teachers, investigators discuss how cutting-edge biomedical research may ultimately contribute to better treatments for cancer patients.

The American Society of Clinical Oncology’s notable research advances include the approval of a new drug for men with advanced prostate cancer that was developed and studied by Memorial Sloan-Kettering researchers.

Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan-Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

The recent FDA approval of axitinib provides a viable treatment option for patients who progress on or cannot tolerate the side effects of other approved drugs for the disease.